Validity of a single-item indicator of treatment side effect bother in a diverse sample of cancer patients.
Pip GriffithsJohn Devin PeipertAndrea LeithAlex RiderLucy MorganDavid CellaKim CocksPublished in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2022)
GP5 exhibited evidence of validity across cancer sites and countries and appeared to measure the same construct across these countries. GP5 has significant promise as a summary indicator of side effect bother.